Successful tarlatamab treatment with concomitant oral corticosteroids and anticonvulsants in small-cell lung cancer with unstable brain metastases: A case report
Year: 2026
Type: article
Study design: Case Report
Abstract: Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager, shows promise for extensive-stage small-cell lung cancer (ES-SCLC), but real-world data in patients with unstable brain metastases are limited. A 50-year-old Japanese man with ES-SCLC progressed after three lines of therapy. Despite prior whole-brain radiation, MRI showed multiple brain metastases with edema and new extracranial lesions. Fourth-line tarlatamab with prophylactic dexamethasone (2 mg/day) and levetiracetam (1000 mg/day) was completed without cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), resulting in tumor reduction. The SCLC patient with unstable brain metastases avoided CRS and ICANS during treatment with dexamethasone, levetiracetam, and tarlatamab.
Source: Respiratory Investigation
Institution: University of Tsukuba
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,000
OpenAlex ID: W7225187434
